Table 4.
Odds ratios and 95% confidence intervals for the association between metabolic syndrome and Type I/II endometrial cancer, SEER-Medicare.
| Metabolic conditions | Type I (n=12,956) | Type II (n=1,402) | p-het | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | % | ORa | 95% CI | n | % | ORa | 95% CI | ||
|
|
|||||||||
| Overweight/obesity | 869 | 6.7 | 1.97 | 1.81 – 2.15 | 93 | 6.6 | 1.82 | 1.46 – 2.28 | 0.39 |
| Impaired fasting glucose | 3,339 | 25.8 | 1.36 | 1.29 – 1.42 | 422 | 30. 1 | 1.44 | 1.28 – 1.63 | 0.27 |
| High blood pressure | 8,801 | 67. 9 | 1.35 | 1.30 – 1.42 | 954 | 68 | 1.17 | 1.04 – 1.32 | 0.06 |
| High triglycerides | 4,895 | 37. 8 | 1.17 | 1.12 – 1.23 | 543 | 38. 7 | 1.17 | 1.04 – 1.31 | 0.83 |
| Metabolic syndromeb | |||||||||
| NCEP-III | 1,936 | 14. 9 | 1.41 | 1.32 – 1.50 | 242 | 17. 3 | 1.42 | 1.22 – 1.65 | 0.58 |
| IDF | 580 | 4.5 | 2.03 | 1.83 – 2.26 | 74 | 5.3 | 2.24 | 1.74 – 2.88 | 0.53 |
ORs adjusted for diagnosis date, age, race/ethnicity, registry area, and tobacco use.
NCEP-III: US National Cholesterol Education Program Adult Treatment Panel III defines metabolic syndrome as the presence of at least three of the following conditions: central adiposity/elevated waist circumference, hypertension, high triglycerides, low HDL cholesterol, and impaired fasting glucose;
IDF: International Diabetes Foundation defines metabolic syndrome as the presence of central adiposity/elevated waist circumference plus any 2 of the other factors (impaired fasting glucose, hypertension, low HDL cholesterol, high triglycerides).